Kadena Sees Christmas Rally with Yield Farming, NFTs in Focus
Ethereum (ETH) wannabe competitor kadena (KDA) has continued to soar higher in the market over Christmas on hopes that the protocol will bring improvements to everything from smart contract creation to non-fungible token...
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
As of 10:37 UTC, KDA traded at USD 15.31, up 12% for the past 24 hours. The token is currently ranked as the 70th most valuable cryptoasset by market capitalization (USD 2.47bn)....
Read More: Kadena Sees Christmas Rally with Yield Farming, NFTs in Focus
Why this matters
This nft story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on CryptonewsRelated market context
As Ethereum turns 11 years old it hosts $148B in stablecoins, but daily mainnet revenue just fell to $330k
Ethereum turned 11 on July 30, the anniversary of the day users generated and loaded the Frontier genesis block in 2015. In its fi...
Bitcoin And Ethereum Edge Higher As Traders Watch Altcoin Rotation
Bitcoin and Ethereum edged higher into July 31, while a small shift in market dominance suggested traders were again watching whet...
Ethereum Turns 11 With $148B Stablecoin Base But Cooler Mainnet Fees
Ethereum has turned 11, and the network’s birthday arrives with a very Ethereum-style contradiction: it is still one of the most i...
Bernstein sees 78% upside for Robinhood as tokenization, prediction markets expand its crypto business
Bernstein held its $160 Robinhood price target, citing tokenization and prediction markets as Robinhood's next crypto growth drive...
Elon Musk Grok AI Predicts Ethereum Will Hit This Price by End of 2026
Grok AI predicts a massive breakout for Ethereum, and this price prediction sets the bar unusually high. The bull case runs to $6,...
Biotech company asks shareholders to dilute stock by 951% to hoard illiquid crypto token instead of funding its own drug
Enlivex, a Nasdaq-listed biotechnology company, is asking shareholders to authorize up to $800 million of financing tied to the RA...